Insulet (NASDAQ:PODD) Sets New 52-Week Low – Time to Sell?

Insulet Corporation (NASDAQ:PODD)’s stock price hit a new 52-week low during trading on Friday . The company traded as low as $220.28 and last traded at $226.71, with a volume of 300006 shares changing hands. The stock had previously closed at $236.07.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. Leerink Partners dropped their price objective on shares of Insulet from $386.00 to $360.00 and set an “outperform” rating for the company in a research note on Thursday, February 19th. Stifel Nicolaus reduced their price objective on Insulet from $370.00 to $350.00 and set a “buy” rating on the stock in a research report on Wednesday, February 4th. Truist Financial cut their target price on shares of Insulet from $390.00 to $360.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Zacks Research cut shares of Insulet from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 5th. Finally, TD Cowen lowered shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 price objective for the company. in a research report on Monday, January 26th. Twenty analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $354.24.

Insulet Price Performance

The company has a fifty day simple moving average of $259.73 and a 200-day simple moving average of $298.06. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.81 and a quick ratio of 2.15. The company has a market cap of $15.69 billion, a P/E ratio of 63.64, a PEG ratio of 1.43 and a beta of 1.42.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The firm had revenue of $783.80 million for the quarter, compared to analyst estimates of $768.31 million. During the same period in the previous year, the firm earned $1.15 earnings per share. Insulet’s quarterly revenue was up 31.2% on a year-over-year basis. On average, sell-side analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Transactions at Insulet

In other news, Director Michael R. Minogue acquired 2,030 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was acquired at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the acquisition, the director owned 17,483 shares in the company, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.39% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Sage Mountain Advisors LLC raised its stake in shares of Insulet by 4.6% during the 3rd quarter. Sage Mountain Advisors LLC now owns 743 shares of the medical instruments supplier’s stock worth $229,000 after purchasing an additional 33 shares in the last quarter. Glenmede Investment Management LP grew its stake in shares of Insulet by 1.6% in the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after buying an additional 35 shares in the last quarter. Curi Capital LLC raised its position in Insulet by 0.8% during the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after acquiring an additional 36 shares in the last quarter. WINTON GROUP Ltd lifted its stake in Insulet by 0.9% in the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock valued at $1,261,000 after acquiring an additional 37 shares during the last quarter. Finally, Evelyn Partners Investment Management Services Ltd increased its position in Insulet by 28.7% during the second quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier’s stock worth $55,000 after buying an additional 39 shares during the last quarter.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.